Welcome to our dedicated page for Petvivo Hldgs SEC filings (Ticker: PETV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PetVivo Holdings, Inc. (PETV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nevada corporation with Commission File Number 001-40715, PetVivo submits current reports, periodic reports and exhibits that document material events, governance changes, financing transactions and investor communications related to its animal health and veterinary AI businesses.
For PetVivo, Form 8-K current reports are particularly relevant. Recent 8-K filings have covered topics such as the appointment and resignation of directors, changes in board size, entry into note conversion agreements with shareholders, and the furnishing of investor presentations under Regulation FD. These filings can give investors insight into PetVivo’s corporate governance, capital structure adjustments and how it communicates its strategy around products like SPRYNG with OsteoCushion technology, PrecisePRP and the PetVivo.ai platform.
In addition to current reports, investors may consult PetVivo’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for detailed information on business operations, risk factors, financial statements and segment discussions related to its veterinary medical devices, regenerative products and AI initiatives. Form 4 and other ownership filings, when filed, can be used to monitor equity transactions by directors, officers and significant shareholders.
Stock Titan enhances these filings with AI-powered summaries that explain key points in clear language, helping readers interpret complex disclosures such as note conversions, licensing agreements or board changes. Real-time updates from EDGAR ensure that new PETV filings appear promptly, while structured access to exhibits like investor presentations allows users to review the same materials referenced in PetVivo’s Regulation FD communications.
PetVivo Holdings, Inc. filed a current report to furnish an updated investor presentation under Regulation FD. Company representatives plan to use this presentation at investor conferences and other forums, and it is attached as Exhibit 99.1 and incorporated into the report by reference.
The investor presentation, dated March 2026, may also be used with investors, analysts and others and on the company’s website. The information is being furnished, not filed, so it is not subject to certain Exchange Act liabilities or automatically incorporated into Securities Act or Exchange Act registration statements.
PetVivo Holdings, Inc. reported another loss-making quarter for the period ended December 31, 2025, and disclosed substantial doubt about its ability to continue as a going concern. Quarterly revenue fell to $286,108 from $583,313 a year earlier, while the net loss available to common stockholders widened to $2,316,455. For the nine months, revenue was $886,892 versus $907,783, with a net loss of $7,788,904. Cash dropped to just $18,164, against an accumulated deficit of $98,987,394. The company shifted away from prior distributors, now relying heavily on Vedco for most sales, and added new licensing agreements for PrecisePRP and an AI platform that it expects to drive future revenue.
PetVivo Holdings, Inc. reported a change in its Board of Directors. On January 26, 2026, director Spencer Breithaupt resigned from the Board, effective that day. The company states his resignation was not due to any disagreement over operations, policies, or practices.
Following his departure, the Board reduced its size from seven to six directors and does not plan to immediately fill the vacancy, though it may add a seventh director in the future at its discretion. The Board expressed appreciation for Mr. Breithaupt’s leadership, guidance, and contributions during his service.
PetVivo Holdings, Inc. furnished a new investor presentation as part of a current report. Representatives plan to use this January 2026 presentation at investor conferences, in other forums, and on the company’s website.
The presentation is included as Exhibit 99.1 and is furnished under Regulation FD and Item 7.01, meaning it is not deemed filed for liability purposes under the Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced. Management notes that the information is summary in nature and may be updated over time through future SEC reports, press releases, or other public disclosures.
PetVivo Holdings, Inc. investor updates ownership report. Individual shareholder Stanley Cruden reports beneficial ownership of 3,620,163 shares of PetVivo common stock, representing 9.37% of the class, as of the event date of 12/31/2025. He has sole power to vote and dispose of all these shares and reports no shared voting or dispositive power.
The certification states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PetVivo Holdings, Inc., nor in connection with any control-related transaction, other than activities solely in connection with a nomination under the cited proxy rule.
A.L. Sarroff Fund, LLC, a 10% owner of PetVivo Holdings, Inc., reported a series of acquisitions of PetVivo common stock between October 18 and December 31, 2024. The transactions include numerous open-market purchases coded "P" at prices generally between $0.46 and $0.57 per share, as well as several entries coded "C" at $0.46 per share. After the final reported purchase of 16,001 shares at $0.57 on December 31, 2024, the fund held 7,740,579 shares of PetVivo common stock in direct ownership.
According to a footnote, Alan L. Sarroff is the Chief Executive Officer and Managing Member of A.L. Sarroff Fund, LLC and is deemed to beneficially own and have sole voting and dispositive power over the fund’s securities.
A.L. Sarroff Fund, LLC, a more than 10% owner of PetVivo Holdings, Inc. (PETV), filed a Form 4 detailing extensive insider activity in 2024. The fund reported multiple open-market purchases of PetVivo common stock between April 5 and October 15, 2024 at prices ranging from
These transactions included warrant exercises that delivered shares, such as 770,767 common shares on
A.L. Sarroff Fund, LLC, a 10% owner of PetVivo Holdings, Inc., reported several equity transactions. On October 26, 2023, the fund acquired 164,340 shares of common stock at $0.73 per share, bringing its holdings to 1,748,251 common shares.
On December 15, 2023, the fund purchased an additional 111,112 common shares at $0.90 per share, increasing its position to 1,859,363 common shares. The same day, it bought 111,112 warrants with a $1.50 exercise price, each warrant exercisable for one share of common stock and expiring on December 15, 2026. A footnote states that Alan L. Sarroff, as Chief Executive Officer and Managing Member of the fund, is deemed to beneficially own and have sole voting and dispositive power over the fund’s securities.
PetVivo Holdings has a new major shareholder group disclosed in a Schedule 13D. A.L. Sarroff Fund, LLC, together with Alan and Eileen Sarroff, report beneficial ownership of 13,933,204 shares of common stock, representing approximately 36.1% of the company based on 33,580,630 shares outstanding as of November 14, 2025, and assuming the exercise of warrants to purchase 5,005,008 shares.
All of these shares are held with shared voting and dispositive power; none of the reporting persons has sole power over the shares. The position was built for investment purposes through open‑market purchases and private placements using personal funds. The reporting persons state they will continue to review their investment and may increase or decrease their holdings or economic exposure, including through derivatives such as swaps or options, but they do not currently outline specific corporate actions beyond standard possibilities referenced in Schedule 13D.
PetVivo Holdings, Inc. reported that its Board of Directors recognized the resignation of director Michael Eldred, effective January 9, 2026. The company stated that his resignation was not due to any disagreement with the company on operations, policies, or practices. In response, the Board decided to reduce its size from eight to seven directors and will not fill the resulting vacancy at this time. The Board formally expressed its appreciation for Mr. Eldred’s service and contributions.